Agoracom Blog Home

Posts Tagged ‘datametrex’

VIDEO – Datametrex $DM.ca $DTMXF CEO Talks Record-Breaking FY2020 with $12.3M In Revenue, Covid-19 Test Kits and More $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:12 PM on Friday, April 30th, 2021

When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.

Financial Highlights for year ending December 31, 2020:

  • Revenue of $12.3M vs. $3.4M for FY 2019
  • An increase of 264%

We sat down with CEO Marshall Gunter to discuss these highlights, the COVID-19 landscape, telemedicine, 2021 plans, and more.

Check out the interview down below.

Datametrex $DM.ca $DTMXF Announces OTCQB Listing $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by Jesse Champagne at 10:54 AM on Monday, April 19th, 2021
Datametrex ai logo 500x172 400 138
  • Company’s common shares will begin trading on the OTCQB® Venture Market (“OTCQB”) today, April 19, 2021 under the current stock symbol “DTMXF”
  • Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. “

Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that after a successful application process for the OTCQB® Venture Market (“OTCQB”), the Company’s common shares will begin trading on the OTCQB today, April 19, 2021, at the opening of the market under the current stock symbol “DTMXF” and will remain listed on the TSX Venture Exchange under the ticker symbol “DM”.

Existing U.S. shareholders of Datametrex AI Limited shares, previously quoted on the OTC® Pink Open Market, will now be quoted on the OTCQB without any further action needed.

Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. The quotation on the OTCQB is anticipated to enhance liquidity by providing current and prospective investors with an easily accessible and transparent trading platform where they go and obtain Real Time quotes and market information.”

About OTCQB

The OTCQB® Venture Market is the premier marketplace for entrepreneurial and development stage US and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. The ability to have the Company’s shares electronically transferred between brokerages in the US is significantly more convenient and reduces the costs incurred in trading shares. When shares are able to trade electronically, existing investors benefit from greater liquidity and execution speeds, while opening the door to new investors that may have been previously restricted from the Company’s shares.

To read more, click here.

Datametrex $DM.ca Secures Authorization by Health Canada for PCL COVID19 Rapid Antigen Test Kit $DTMXF $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by Jesse Champagne at 1:58 PM on Tuesday, March 23rd, 2021
Datametrex ai logo 500x172 400 138

*PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed.

*They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

Toronto, Ontario–(Newsfile Corp. – March 23, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that Heath Canada (“HC”) has approved the PCL Inc.’s (“PCL”) COVID19 AG Rapid test kit (“PCL Antigen”), an antigen point-of-care rapid test device under the Interim Order (“IO”) Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19. Datametrex made an application for the PCL Antigen under IO on August 24, 2020, Respecting the Importation and Sale of Medical Devices for use in relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act. (link: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/authorized/list.html)

According to the manufacturer, PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed. They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

View the PCL Antigen test manual video by clicking the link: PCL COVID-19 ANTIBODY TEST

The following certifications have been awarded to these PCL Antigen test kits: CE Certificate, Korea KPMG, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East, Qatar and UAE, India, Russia, 3 countries in Latin America, Guatemala, Ecuador, and Colombia.

“Datametrex has been given another incredible opportunity to sell an additional medical testing device in Canada with the antigen test, with a supplier with outstanding medical devices in PCL. With the highly contagious new variant, and the second wave and possible third wave of COVID-19 in Canada and throughout the world, Datametrex believes an increase in testing capacity is critical to test and protect people,” said Marshall Gunter, CEO of Datametrex AI Limited.

The Company’s ability to fulfill any purchase order for the PCL Rapid test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little, or no upfront costs associated with importing and selling these test kits.

To read more, click here.

Datametrex $DM.ca $DTMXF Announces Letter of Intent of Telemedicine Company $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by Jesse Champagne at 1:34 PM on Tuesday, March 23rd, 2021
This image has an empty alt attribute; its file name is 72321fd3-ab1d-40a2-af37-397a2993ccb4.png
  • Company to acquire 100% of the issued and outstanding share capital of a telemedicine company that is a subscription service that connects patients with providers or doctors in real-time.
  • Datametrex intends to integrate the Target’s platform into the Company’s core AI technology.

Toronto, Ontario–(Newsfile Corp. – March 23, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has entered into a Letter of Intent (the “LOI“) on March 22, 2021, to acquire 100% of the issued and outstanding share capital of a telemedicine company (the “Target”), an arm’s length privately held company, incorporated under the laws of the Province of British Columbia.

Pursuant to its confidentiality obligations, the identity of the Target is confidential and will be subsequently disclosed if the parties enter into a Definitive Agreement (as defined below).

Subject to the completion of satisfactory mutual due diligence within thirty (30) days from the date of the LOI by Datametrex and Target, respectively, pursuant to the terms and conditions of the LOI, Datametrex and the Target will enter into a Definitive Agreement (“Definitive Agreement”).

“The impact of the acquisition of this telemedicine AI business cannot be minimized. The demand for telemedicine continues to be a large area of growth particularly with the current pandemic. We believe that adding this telemedicine element to our existing AI business will drive significant value for our stakeholders,” said Marshall Gunter, Datametrex’s Chief Executive Officer.

The Target is a telemedicine company that is a subscription service that connects patients with providers or doctors in real time. Datametrex intends to integrate the Target’s platform into the Company’s core AI technology.

The Transaction

It is anticipated that the Transaction will be structured as a share acquisition. Datametrex will acquire all of the securities of Target. It is anticipated that the Definitive Agreement will be signed on or before April 15, 2021 or such other date as mutually agreed to by the parties.

Closing of the Transaction is subject to a number of conditions, including but not limited to the following:

  • The Corporation will acquire the Target Shares for an aggregate purchase price of CAD $12 million (the “Purchase Price”). The Purchase Price shall be satisfied through the issuance of an aggregate of 60 million units (the “Consideration Units”). Each Consideration Unit shall comprise one common share in the capital of the Company (a “Consideration Share”) and a common share purchase warrant (a “Consideration Warrant”) in the capital of the Corporation with an exercise price of $0.20 per Consideration Unit; and
  • Each Consideration Unit shall entitle the holder thereof to acquire one common share in the capital of the Corporation at an exercise price of $0.25 per share for a period of 24 months from date of issuance;
  • Issuance of the Consideration Units and its underlying securities shall be subject to the receipt of regulatory approvals including, without limitation, the approval of the TSX Venture Exchange (“TSXV“) and other conditions and will be subject to statutory hold periods under applicable securities legislation;
  • The Board of Directors and shareholders of Target approving the Definitive Agreement and the transfer of the Target shares to the Company in exchange for the payment of the Purchase Price; and
  • The Company and the Target completing and being satisfied with the results of its due diIigence investigations; and
  • The Transaction closing on or before April 15, 2021.

On closing of the Transaction:

  • Target will become a wholly owned subsidiary of the Company.

Datametrex will not assume any debt of the Target and the proposed acquisition of Target is not expected to constitute a fundamental change or result in a change of business for the Company, nor is it expected to result in a change of control of the Company within the meaning of applicable securities laws and the policies of the TSXV.

To read more, click here.

AGORACOM Small Cap 60: Datametrex $DM.ca $DTMXF Social Media Discovery – Fighting Fake News and Disinformation – Fighting #Covid19 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:15 PM on Monday, March 22nd, 2021

VIDEO – Datametrex AI $DM.ca $DTMXF Discusses Company’s M&A Growth Plans For Artificial Intelligence Division $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 5:46 PM on Monday, March 15th, 2021

Datametrex AI Limited has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.  

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

The company announced that it has entered into an LOI to acquire 100% of Perspectum Drone Inspection Services Ltd. an arm’s length privately held artificial intelligence drone imaging predictive analytic services company.

Perspectum is a drone based imaging predictive analytics artificial intelligence (AI) services company, currently focusing on environmental and safety predictive analysis. Datametrex intends to expand the Perspectum platform into the Company’s core Cybersecurity business by integrating the Company’s AI with Perspectum.

“The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth. As businesses and countries continue to work towards zero emissions and carbon neutral footprints, we believe that adding this imaging predictive AI element to our existing cybersecurity business will drive significant value for our stakeholders.”, said Marshall Gunter, Datametrex’s Chief Executive Officer.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

Sit back, relax and watch this powerful interview with Datametrex CEO Marshall Gunter.

Datametrex $DM.ca $DTMXF Announces Acquisition of an Imaging Predictive AI Company $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by Jesse Champagne at 11:16 AM on Wednesday, March 10th, 2021

Datametrex Announces Acquisition of an Imaging Predictive AI Company

  • Datametrex to buy drone-based AI inspection services company for $3MM
  • “The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth,” said CEO Marshall Gunter.

Toronto, Ontario–(Newsfile Corp. – March 10, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has entered into a Letter of Intent (the “LOI“) to acquire 100% of Perspectum Drone Inspection Services Ltd. (“Perspectum”), an arm’s length privately held artificial intelligence drone imaging predictive analytic services company, incorporated under the laws of Alberta.

Subject to the completion of satisfactory mutual due diligence within thirty (30) days by Datametrex and Perspectum, under the terms and conditions of the LOI, Datametrex and Perspectum will enter into a Definitive Agreement (“Definitive Agreement”), pursuant to which Datametrex will acquire 100% of the issued and outstanding shares (“Transaction“) of Perspectum.

“The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth. As businesses and countries continue to work towards zero emissions and carbon neutral footprints, we believe that adding this imaging predictive AI element to our existing cybersecurity business will drive significant value for our stakeholders.”, said Marshall Gunter, Datametrex’s Chief Executive Officer.

Perspectum is a drone based imaging predictive analytics artificial intelligence (AI) services company, currently focusing on environmental and safety predictive analysis. Datametrex intends to expand the Perspectum platform into the Company’s core Cybersecurity business by integrating the Company’s AI with Perspectum.

The Transaction

It is anticipated that the Transaction will be structured as a share acquisition. Datametrex will acquire all of the securities of Perspectum. It is anticipated that the Definitive Agreement will be signed on or before March 31, 2021.

Closing of the Transaction is subject to a number of conditions, including but not limited to the following:

  • The Company will acquire all shares of Perspectum for an aggregate purchase price of CAD $3 million (“Purchase Price”) to be satisfied through the issuance of common shares (“Consideration Shares”) of Datametrex. The number of Consideration Shares to be issued shall be determined based on the Volume Weighted Average Price (“VWAP”) of the common shares of the Company on the facilities of the TSX Venture Exchange for the thirty days prior to the closing date.
  • The Company will place a number of shares equivalent in value to $500,000 in escrow (“Escrow Shares”). The Escrow Shares held in escrow will automatically be released when Perspectum achieves gross revenue of $600,000 following the closing of the Transaction. Should Perspectum not achieve $600,000 of gross revenue in the 16 month period following the Transaction, the Escrow Shares will be cancelled.
  • Issuance of the Consideration Shares shall be subject to the receipt of regulatory approvals including, without limitation, the approval of the TSX Venture Exchange (“TSXV“) and other conditions and will be subject to statutory hold periods.
  • Datametrex will pay a 5% finders’ fee in connection with the Transaction.
  • The Board of Directors and shareholders of Perspectum approving the Definitive Agreement and the transfer of the Perspectum shares to the Company in exchange for the payment of the Purchase Price.
  • The Company completing and being satisfied with the results of its due diIigence investigations.
  • The Transaction to be completed by April 30, 2021.

On closing of the Transaction,

  • Perspectum will become a wholly owned subsidiary of the Company.
  • Ty Pfeifer shall be appointed President of the subsidiary.
  • The Company shall fund the subsidiary with $550,000 to allow the subsidiary to complete its AI intergration and purchase a second drone/camera platform.

To read more, click here.

Datametrex $DM.ca $DTMXF Announces Closing of Acquisition with Concierge Medical $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:38 AM on Thursday, February 11th, 2021
  • Closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
  • Concierge is an arm’s length private telehealth and medical concierge services

Toronto, Ontario–(February 11, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex) is pleased to announce that further to its press releases dated January 7, 2021 and January 22, 2021, it has closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).

Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

Terms of the Transaction

Pursuant to the Definitive Agreement, the Company issued 4,411,764 common shares in the capital of the Company (the “Common Shares“) to the Concierge Shareholders at a price of $0.17 per Common Share for an aggregate purchase price of $750,000.

No finder’s fee was payable in connection with the Transaction.

“Hospital ER’s and health practitioners’ clinics are making a strong push for patients who have mild symptoms to use telehealth platforms during the pandemic crisis to help alleviate the strain on emergency rooms and doctors’ offices and I believe this will continue after the pandemic crisis is over,” commented Dr. Jibran Sharif, MD, founder, and CEO of Concierge.

“Telemedicine visits are booming as doctors and patients have adopted social distancing amid the coronavirus crisis, and with the concierge services Dr. Sharif provide, we envision an end to end turnkey solution for patient healthcare,” said Marshall Gunter, CEO of Datametrex, with respect to the closing of the Transaction.

Operations of Concierge Upon Completion of the Transaction

Concierge has become a wholly-owned operating subsidiary of the Company. The Company has appointed Andrew Ryu, Marshall Gunter, and Dr. Jibran Sharif as the new board of the directors of Concierge, and Dr. Sharif is appointed as the President of Concierge following the closing of the Transaction (the “Closing“). In addition, concurrent with the Closing, the Company has entered into a employment agreement with the founder and President of Concierge, Dr. Jibran Sharif. In addition to his role as President of Concierge, Dr. Jibran Sharif will become the Chief Medical Officer of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/755157-datametrex-announces-closing-of-acquisition-with-concierge-medical/messages/2303196#message

Datametrex AI $DM.ca $DTMXF Tracks Social Media Data to Understand “Reddit” Effect $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, February 4th, 2021
  • Announced that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices.
  • Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends.
  • NexaSMART stands for “Social Media Automated Reporting Technology.”

Toronto, Ontario–(February 4, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices. Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends. NexaSMART stands for “Social Media Automated Reporting Technology.”

Many investor eyes have turned to the subject of discussion forums such as Reddit that can have impact on the stock market and the price rise of specific stocks, sometimes even despite poor business indicators. According to the Wall Street Journal, mainstream journalists have linked cryptocurrency, stock speculation and conspiracy theories together as a formula for volatility in markets.1

In todays environment, investors rely even more on their investments to secure a comfortable retirement. We believe it is vital for people to know what the truth is and what is fiction when searching for information online that can have a major impact on their returns.

Nexalogy, the wholly owned subsidiary of Datametrex AI Limited, has expertise in disinformation research, and is able to track phenomenon of this nature as evidenced in NexaSMART reports (Read Report Here).

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754635-datametrex-ai-tracks-social-media-data-to-understand-reddit-effect/messages/2301971#message

Datametrex $DM.ca $DTMXF Announces Investor Webinar $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:52 PM on Wednesday, February 3rd, 2021

Toronto, Ontario–(February 3, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that senior management will be hosting an investor update webinar on Tuesday, February 9, 2021, at 1:30 p.m. EST for a corporate update on the latest developments of the Artificial Intelligence technologies and COVID-19 test kits.

Webinar Details:

Date: Tuesday, February 9, 2021

Time: 1:30 p.m. ET

Registration Link: https://us02web.zoom.us/webinar/register/WN_Ge6setHBRAyeBLbKaUIUHQ

Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754580-datametrex-announces-investor-webinar/messages/2301880#message